Vertex Pharmaceuticals Incorporated Stock Return On Asset
| VRTX34 Stock | BRL 604.58 7.92 1.29% |
Vertex Pharmaceuticals Incorporated fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
Vertex |
Vertex Pharmaceuticals Incorporated Company Return On Asset Analysis
Vertex Pharmaceuticals' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Vertex Pharmaceuticals Return On Asset | 0.17 |
Most of Vertex Pharmaceuticals' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals Incorporated is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Vertex Pharmaceuticals Incorporated has a Return On Asset of 0.1733. This is 101.98% lower than that of the Healthcare sector and 100.73% lower than that of the Biotechnology industry. The return on asset for all Brazil stocks is notably lower than that of the firm.
Vertex Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is rated fifth in return on asset category among its peers.
Vertex Fundamentals
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 372.17 B | |||
| Shares Outstanding | 1.03 B | |||
| Price To Earning | 18.08 X | |||
| Price To Book | 6.20 X | |||
| Price To Sales | 49.16 X | |||
| Revenue | 8.93 B | |||
| Gross Profit | 7.55 B | |||
| EBITDA | 4.29 B | |||
| Net Income | 3.32 B | |||
| Cash And Equivalents | 6.71 B | |||
| Cash Per Share | 6.46 X | |||
| Total Debt | 509.8 M | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 4.61 X | |||
| Book Value Per Share | 13.53 X | |||
| Cash Flow From Operations | 2.64 B | |||
| Earnings Per Share | 17.03 X | |||
| Price To Earnings To Growth | 0.42 X | |||
| Number Of Employees | 4.8 K | |||
| Beta | 0.46 | |||
| Market Capitalization | 403.29 B | |||
| Total Asset | 18.15 B | |||
| Net Asset | 18.15 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals Incorporated's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals Incorporated based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Vertex Stock
Vertex Pharmaceuticals financial ratios help investors to determine whether Vertex Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Vertex with respect to the benefits of owning Vertex Pharmaceuticals security.